Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Takon, Inyang ^a  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; APPETITE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BODY HEIGHT; BODY WEIGHT; CASE REPORT; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IMMEDIATE RELEASE PREPARATION; IMPULSIVENESS; LEARNING DISORDER; LOW DRUG DOSE; MALE; MEDICAL TECHNOLOGY; MENTAL INSTABILITY; MODIFIED RELEASE PREPARATION; MORNING DOSAGE; PATIENT COMPLIANCE; PATIENT REFERRAL; PRESCHOOL CHILD; PSYCHOPHARMACOTHERAPY; REVIEW; SCHOOL CHILD; SIDE EFFECT; SOCIAL INTERACTION; STIGMA; SUSTAINED RELEASE PREPARATION; SYMPTOM; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT REDUCTION;

EID: 80053349715     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-25     Document Type: Review

References (43)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948. 10.1176/appi.ajp.164.6.942, 17541055.
2. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am 1999, 46:915-927. vii, 10.1016/S0031-3955(05)70163-2, 10570696.
3. Cutting LE, Koth CW, Mahone EM, Denckla MB. Evidence for unexpected weaknesses in learning in children with attention-deficit/hyperactivity disorder without reading disabilities. J Learn Disabil 2003, 36:259-269. 10.1177/002221940303600305, 15515646.
4. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001, 40:508-515. 10.1097/00004583-200105000-00009, 11349694.
5. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248. 10.1016/S0140-6736(05)66915-2, 16023516.
6. Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, Wilens TE, Frazier E, Johnson MA. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002, 159:36-42. 10.1176/appi.ajp.159.1.36, 11772687.
7. Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006, 67(Suppl 8):13-20.
8. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007, 96:1269-1274. 10.1111/j.1651-2227.2007.00430.x, 17718779.
9. NICE Diagnosis and Management of ADHD in Children, Young People and Adults. National Clinical Practice Guideline Number 2009, London, UK: The British Psychological Society/The Royal College of Psychiatrists, 72, NICE.
10. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999, 38:503-512. 10.1097/00004583-199905000-00011, 10230181.
11. Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983, 72:56-59.
12. Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990, 86:226-237.
13. Swanson J, Kinsbourne M, Roberts W, Zucker K. Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978, 61:21-29.
14. Patrick KS, Straughn AB, Jarvi EJ, Breese GR, Meyer MC. The absorption of sustained-release methylphenidate formulations compared to an immediate-release formulation. Biopharm Drug Dispos 1989, 10:165-171. 10.1002/bdd.2510100206, 2706316.
15. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999, 340:780-788. 10.1056/NEJM199903113401007, 10072414.
16. Horrigan JP, Kohli RR. The impact of dosing frequency on psychostimulant compliance in ADHD. NIMH-42nd Annual NCDEU Meeting 2002, Poster 56 10-13. Boca Raton, FL.
17. Wigal SB, Sanchez DY, DeCory HH, D'Imperio JM, Swanson JM. Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 2003, 3:46-63.
18. Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von MG, Gunter M, Hassler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I93-101.
19. Findling RL, Quinn D, Hatch SJ, Cameron SJ, DeCory HH, McDowell M. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006, 15:450-459. 10.1007/s00787-006-0565-0, 16791541.
20. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107:E105. 10.1542/peds.107.6.e105, 11389303.
21. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003, 5:545-555. 10.2165/00148581-200305080-00005, 12895137.
22. Silva R, Muniz R, Pestreich LK, Brams M, Childress A, Lopez FA. Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005, 15:637-654. 10.1089/cap.2005.15.637, 16190795.
23. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004, 113:e206-e216. 10.1542/peds.113.3.e206, 14993578.
24. Equasym XL SPC (UK) Equasym XL SPC (UK). Equasym XL SPC (UK)., http://www.medicines.org.uk/EMC/medicine/15804/SPC/Equasym+XL+10+mg%2c+20+mg+or+30+mg+Capsules/
25. Concerta XL SPC (UK) Concerta XL 18 mg-36 mg prolonged release tablets SPC (UK). Concerta XL SPC (UK)., http://emc.medicines.org.uk/medicine/8382/SPC/ConcertaXL18mg-36mgprolongedreleasetablets/
26. Medikinet XL SPC (UK) Medikinet XL SPC (UK). Medikinet XL SPC (UK)., http://emc.medicines.org.uk/medicine/19510/SPC/MedikinetXL/
27. Sonuga-Barke EJ, Coghill D, Wigal T, DeBacker M, Swanson J. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009, 19:683-690. 10.1089/cap.2009.0024, 20035586.
28. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47:994-1009.
29. Meijer WM, Faber A, van den BE, Tobi H. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci 2009, 31:509-516. 10.1007/s11096-009-9302-3, 2730446, 19562500.
30. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005, 90:801-806. 10.1136/adc.2004.056952, 1720538, 16040876.
31. Spencer T, Biederman J, Wilens T. Growth deficits in children with attention deficit hyperactivity disorder. Pediatrics 1998, 102:501-506.
32. Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002, 41:443-449. 10.1097/00004583-200204000-00017, 11931601.
33. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002, 109:E39. 10.1542/peds.109.3.e39, 11875167.
34. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004, 4:28. 10.1186/1471-244X-4-28, 524494, 15458569.
35. Sonuga-Barke EJ, Coghill D, Markowitz JS, Swanson JM, Vandenberghe M, Hatch SJ. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 2007, 46:701-710. 10.1097/chi.0b013e31804659f1, 17513982.
36. Sonuga-Barke EJ, Van LP, Swanson JM, Coghill D, Wigal S, Vandenberghe M, Hatch S. Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis. Eur Child Adolesc Psychiatry 2008, 17:245-254.
37. Sonuga-Barke EJ, Coghill D, DeBacker M, Swanson J. Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings?. J Child Adolesc Psychopharmacol 2009, 19:691-698. 10.1089/cap.2009.0027, 20035587.
38. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008, 47:180-188. 10.1097/chi.0b013e31815d9af7, 18182963.
39. Saigal S. Follow-up of very low birthweight babies to adolescence. Semin Neonatol 2000, 5:107-118. 10.1053/siny.1999.0003, 10859705.
40. Seubert DE, Stetzer BP, Wolfe HM, Treadwell MC. Delivery of the marginally preterm infant: what are the minor morbidities?. Am J Obstet Gynecol 1999, 181:1087-1091. 10.1016/S0002-9378(99)70086-4, 10561623.
41. Stenninger E, Flink R, Eriksson B, Sahlen C. Long-term neurological dysfunction and neonatal hypoglycaemia after diabetic pregnancy. Arch Dis Child Fetal Neonatal Ed 1998, 79:F174-F179. 10.1136/fn.79.3.F174, 1720863, 10194986.
42. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med 2010, 11:652-658. 10.1016/j.sleep.2010.02.012, 20620109.
43. Kim HW, Yoon IY, Cho SC, Kim BN, Chung S, Lee H, Kim CW, Park SK, Yoo HJ. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2010, 25:107-115. 10.1097/YIC.0b013e3283364411, 20093941.